112.09
0.03%
-0.03
iRhythm Technologies Inc stock is currently priced at $112.09, with a 24-hour trading volume of 262.17K.
It has seen a -0.03% decreased in the last 24 hours and a +7.52% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $112.1 pivot point. If it approaches the $109.8 support level, significant changes may occur.
iRhythm Technologies Inc Stock (IRTC) Financials Data
iRhythm Technologies Inc (IRTC) Revenue 2024
IRTC reported a revenue (TTM) of $492.68 million for the quarter ending December 31, 2023, a +19.90% rise year-over-year.
iRhythm Technologies Inc (IRTC) Net Income 2024
IRTC net income (TTM) was -$123.41 million for the quarter ending December 31, 2023, a -6.24% decrease year-over-year.
iRhythm Technologies Inc (IRTC) Cash Flow 2024
IRTC recorded a free cash flow (TTM) of -$90.53 million for the quarter ending December 31, 2023, a -71.31% decrease year-over-year.
iRhythm Technologies Inc (IRTC) Earnings per Share 2024
IRTC earnings per share (TTM) was -$4.05 for the quarter ending December 31, 2023, a -4.11% decline year-over-year.
iRhythm Technologies Inc Stock (IRTC) Latest News
iRhythm Technologies to Report First Quarter 2024 Financial Results on May 2, 2024
GlobeNewswire Inc.
iRhythm Technologies (IRTC) Surges 4.2%: Is This an Indication of Further Gains?
Zacks Investment Research
iRhythm Announces Closing of $661.25 Million of 1.50% Convertible Senior Notes Due 2029, Including Full Exercise of Initial Purchasers’ $86.25 Million Option to Purchase Additional Notes
GlobeNewswire Inc.
iRhythm Prices Upsized Offering of $575.0 Million of 1.50% Convertible Senior Notes Due 2029
GlobeNewswire Inc.
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
Benzinga
iRhythm Announces Proposed Offering of $450.0 Million of Convertible Senior Notes
GlobeNewswire Inc.
About iRhythm Technologies Inc
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. Its Zio XT monitor, a single-use, wire-free, and wearable patch-based biosensor, records patient's heartbeats and ECG data. The company was founded in 2006 and is headquartered in San Francisco, California.
Cap:
|
Volume (24h):